Archive for the ‘Erectile Dysfunction / Premature Ejaculation’ Category
Friday, March 5th, 2010
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). "The progression of Zoraxel's clinical program is very encouraging," said Rexahn Chief Executive Officer, Dr...
Friday, March 5th, 2010
News reports coming out of the UK and Australia show evidence of prescription ingredients in many "natural" herb remedies sold on the Internet to treat erectile dysfunction (ED). These popular online supplements, which claim to consist only of homeopathic ingredients, are often improperly labeled and may actually contain dangerous ingredients. Dr. J...
Thursday, February 25th, 2010
Global Health Ventures Inc. (OTCBB:GHLV), or the "Company", is pleased to announce that it has engaged Clinical Investigations Ltd. of United Kingdom to design and carry out the human clinical trials for X-Excite in Europe under the European Regulatory Guidelines (EMEA)...
Thursday, February 25th, 2010
UroToday.com - In permitting longitudinal data analyses of our study cohort of men with erectile dysfunction (ED) and without known previous history of cardiovascular (CV) disease, data linkage has provided us a novel methodological approach in our investigation on the role of ED as a predictor of atherosclerotic CV events...
Wednesday, February 10th, 2010
Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old...
Thursday, January 21st, 2010
Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed. That's the warning just published online by IJCP the International Journal of Clinical Practice...
Thursday, January 21st, 2010
In the first study of its kind, New England Research Institutes, Inc...
Thursday, January 21st, 2010
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, announced today that it received a Notice of Non-Compliance ("Notice") as part of the review process from Health Canada for its New Drug Submission ("NDS") for the Vitaros erectile dysfunction treatment filed in February 2008...
Tuesday, January 12th, 2010
VIVUS, Inc. (Nasdaq: VVUS) announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED)...
Monday, January 4th, 2010
A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms...
Monday, December 28th, 2009
Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem. The importance of this biopsychosocial approach, whether one looks at disorders of desire, arousal or orgasm, is supported by intercultural comparisons, among other data...
Monday, December 28th, 2009
Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem. The importance of this biopsychosocial approach, whether one looks at disorders of desire, arousal or orgasm, is supported by intercultural comparisons, among other data...
Friday, November 20th, 2009
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Results of the double-blind treatment phase of this study, which enrolled patients from the U.S.
Friday, November 20th, 2009
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE)...
Friday, November 20th, 2009
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE)...
Thursday, November 19th, 2009
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED)...
Thursday, November 19th, 2009
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED)...
Thursday, November 12th, 2009
High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals...
Thursday, November 12th, 2009
High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals...
Monday, November 2nd, 2009
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Priapism is a condition of persistent painful penile erection in the absence of sexual desire...
Monday, November 2nd, 2009
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Priapism is a condition of persistent painful penile erection in the absence of sexual desire...